CGON (CG Oncology) Short Percentage of Float


CGON CG Oncology Inc CGON
12 GF Score
Price $71.85
! 6 Warning Signs
View Full Analysis

What is CG Oncology Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CGON vs CRSP, XENE, TGTX: Short Percentage of Float Comparison

For the Biotechnology subindustry, CG Oncology's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where CG Oncology's Short Percentage of Float falls into.


CGON
12GF Score
CG Oncology Inc CGON
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score

Get the complete analysis for CGON

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$71.85
Price